Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, Mara Merluzzi, Antonio Bennati, Vincenzo Maria Perriello, Alessandra Pucciarini, Alessia Santi, Alessandra Venanzi, Valentina Pettirossi, Gianluca Schiavoni, Luisa Tasselli, Stefano Ascani, Stefano Volpetti, Brunangelo Falini
Topics & Concepts
DabrafenibRefractory (planetary science)MedicineLeukemiaOncologyInternal medicineClinical trialHairy cell leukemiaHematologyCancer researchPhases of clinical researchVemurafenibCancerBiologyAstrobiologyMetastatic melanomaMelanoma and MAPK PathwaysChronic Lymphocytic Leukemia ResearchProtein Tyrosine Phosphatases